https://doi.org/10.4081/hmr.v2i5.750

Multiple myeloma

Vol. 2 No. 5: New Drugs in Hematology, Bologna, Italy 5-7 October 2008
Published: June 23, 2009
Abstract Views: 136
PDF: 95
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

J San Miguel
support@pagepress.org
Treatment of Multiple Myeloma (MM) has significantly changed over the last few years. In young patients the use of novel schemes based on Thalidomide, Lenalidomide, or, Bortezomib appear to be superior to VAD as debulky pre-transplant regimens and these schemes do not affect stem cell collection, although some precautions should be taken with Lenalidomide. Interestingly, the initial CR rate obtained with these combinations (particularly with Bortezomib, as shown in two randomized trials) was upgraded following ASCT, which suggests that these novel treatments will not replace ASCT, but will help to enhance its activity, although the EFS and OS of this approach is still unknown. Regarding the role of novel drugs in maintenance therapy after transplant, two randomized trials have shown that Thalidomide maintenance prolongs EFS and OS, particularly in those patients who fail to achieve CR after Transplant. Nevertheless, prolonged treatment may be associated with more resistant relapses to salvage therapy.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

San Miguel, J. (2009). Multiple myeloma. Hematology Meeting Reports (formerly Haematologica Reports), 2(5). https://doi.org/10.4081/hmr.v2i5.750
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).